Global Tumor Necrosis Factor Receptor Superfamily Member 18 Market Size By Type (AMG-228, BMS-986156), By Application (Melanoma, Non-Small Cell Lung Cancer), By Region, And Segment Forecasts, 2023 to...

The Global Tumor Necrosis Factor Receptor Superfamily Member 18 (TNFRSF18) Market was valued at USD 512 million in 2023 and is projected to reach USD 1.32 billion by 2031, growing at a CAGR of 12.6% during the forecast period from 2023 to 2031. TNFRSF18, also known as GITR (Glucocorticoid-Induced TNFR-Related protein), is a key immunomodulatory receptor primarily involved in the regulation of T-cell activity. The rapid growth of this market is driven by the increasing prevalence of cancer and autoimmune diseases, rising interest in immuno-oncology, and ongoing advancements in monoclonal antibodies and cell-based therapies targeting immune checkpoints.

As pharmaceutical and biotechnology companies intensify their research efforts on immune receptor pathways, TNFRSF18 is gaining attention as a novel target for immunotherapeutic interventions aimed at enhancing anti-tumor immune responses while preserving immune homeostasis.

Drivers:

1. Rising Prevalence of Cancer and Autoimmune Disorders:

An increase in cancer incidence globally, especially solid tumors and hematologic malignancies, is a major factor contributing to the market's expansion. The immunomodulatory function of TNFRSF18 makes it a promising therapeutic target for enhancing immune system activation in cancer patients.

2. Growing Investments in Immuno-Oncology:

Biopharmaceutical companies are actively investing in next-generation immunotherapy solutions. TNFRSF18 is being explored in combination therapies with checkpoint inhibitors like PD-1 and CTLA-4 inhibitors, accelerating market growth.

3. Technological Advancements in Monoclonal Antibody and Cell Therapy Development:

Ongoing R&D into engineered antibodies and CAR-T cell therapies that target TNFRSF18 has enabled more targeted and personalized treatment strategies, opening new avenues in cancer immunotherapy.

Restraints:

1. High Development Costs and Regulatory Complexity:

Developing TNFRSF18-targeting biologics involves extensive preclinical and clinical trials, raising the cost burden and delaying product commercialization due to stringent regulatory frameworks.

2. Limited Clinical Evidence:

Despite the promise, there is limited long-term clinical data on TNFRSF18-targeted therapies, especially concerning their safety profiles in chronic use and combination with other immunotherapies.

Opportunity:

1. Emerging Role in Combination Immunotherapies:

TNFRSF18 has shown potential in augmenting the efficacy of existing checkpoint inhibitors. Its inclusion in combination therapy regimens provides a high-impact opportunity for improving patient outcomes, particularly in refractory tumors.

2. Expansion into Autoimmune and Inflammatory Diseases:

Beyond oncology, TNFRSF18 is being investigated for its regulatory role in autoimmune conditions such as multiple sclerosis and rheumatoid arthritis, broadening the target population for potential therapies.

Market by System Type Insights:

Based on system type, the Monoclonal Antibody Therapies segment dominated the market in 2023. These therapies are leading the pipeline due to their specificity, ease of engineering, and well-established manufacturing platforms. However, the Cell-based Therapies segment is expected to witness the highest growth rate owing to the rising adoption of CAR-T and TCR-engineered T cell platforms targeting TNFRSF18 in oncology.

Market by End-use Insights:

In terms of end-use, Biopharmaceutical & Biotechnology Companies held the largest market share in 2023. These organizations are at the forefront of developing TNFRSF18-targeted therapies, supported by extensive R&D investments and clinical trial activities. Academic and Research Institutions also represent a rapidly growing segment, contributing to basic science research and translational studies that propel early-phase innovations.

Market by Regional Insights:

North America led the global TNFRSF18 market in 2023, attributed to its robust biotech ecosystem, favorable regulatory pathways for orphan and immunotherapy drugs, and the presence of major market players and research institutions. Asia-Pacific is expected to grow at the fastest rate due to increasing government funding for cancer research, expanding biotech capabilities in countries like China and India, and rising incidence of target diseases.

Competitive Scenario:

Key players in the Global TNFRSF18 Market include Agenus Inc., Bristol-Myers Squibb, Gilead Sciences (Kite Pharma), Merck & Co., Inc., AbbVie Inc., ImmunoGen Inc., and Novartis AG. These companies are actively engaged in collaborative clinical trials, licensing deals, and the development of combination therapies targeting TNFRSF18 pathways.

Key Market Developments:

2023: Agenus Inc. reported promising Phase I clinical trial data for its GITR agonist antibody in combination with PD-1 inhibitors, demonstrating favorable immune activation in solid tumors.

2024: Bristol-Myers Squibb announced the expansion of its immuno-oncology pipeline with the acquisition of a biotech firm focused on novel TNFRSF-based immunotherapies.

2025: Gilead Sciences received FDA Fast Track Designation for its GITR-CAR-T therapy in advanced hematologic malignancies.

Scope of Work – Global Tumor Necrosis Factor Receptor Superfamily Member 18 Market

Report Metric Details

Market Size (2023) USD 512 million

Projected Market Size (2031) USD 1.32 billion

CAGR (2023–2031) 12.6%

Market Segments By System Type (Monoclonal Antibody Therapies, Cell-based Therapies),

By End-use (Biopharma Companies, Academic Institutions),

By Region (North America, Europe, Asia-Pacific, Latin America, MEA)

Growth Drivers Rising cancer incidence, investment in immuno-oncology, R&D in immune checkpoint therapy

Opportunities Combination therapy with PD-1/CTLA-4 inhibitors, expansion into autoimmune diseases

FAQs:

1. What is the current market size of the Global Tumor Necrosis Factor Receptor Superfamily Member 18 Market?

The market was valued at USD 512 million in 2023.

2. What is the major growth driver of the Global Tumor Necrosis Factor Receptor Superfamily Member 18 Market?

The major driver is the growing application of TNFRSF18-targeted therapies in cancer immunotherapy.

3. Which is the largest region during the forecast period in the Global Tumor Necrosis Factor Receptor Superfamily Member 18 Market?

North America is expected to remain the largest region due to strong biotech research infrastructure and clinical trial activity.

4. Which segment accounted for the largest market share in the Global Tumor Necrosis Factor Receptor Superfamily Member 18 Market?

Monoclonal Antibody Therapies accounted for the largest share in 2023.

5. Who are the key market players in the Global Tumor Necrosis Factor Receptor Superfamily Member 18 Market?

Key players include Agenus Inc., Bristol-Myers Squibb, Gilead Sciences, Merck & Co., and Novartis AG.